Back to News​
Article | News

The Top 25 BioTech and Life Sciences Executives of 2025

Back to Publications​
  • August 19, 2025
Topic/Product:
Alzheimer's, Neurology

Abstract

#15 Xiao-Jun Ma, Phd – CTO, Alamar Biosciences.

The Healthcare Technology Report is pleased to announce The Top 25 BioTech and Life Sciences Executives of 2025. This year’s awardees represent a cross-section of leaders driving scientific, operational, and technological progress across the life sciences industry. They include founders, CEOs, and senior executives at companies developing next-generation therapeutics, building AI-enabled discovery platforms, advancing high-sensitivity diagnostics, and reimagining clinical development and manufacturing. From early-stage ventures to global biopharmaceutical companies, these individuals are shaping the tools, infrastructure, and therapies that define the future of healthcare.

Among them are executives who have led successful IPOs and acquisitions, overseen breakthrough approvals in gene and cell therapy, and helped scale technologies that accelerate drug discovery and delivery. Many have built and commercialized platforms that support not just a single treatment, but entire pipelines. Others are expanding access to care in historically underserved disease areas. Whether pioneering programmable cell therapies, launching smart manufacturing systems, or applying AI to decode disease biology, this year’s honorees stand out for their ability to translate complex science into meaningful outcomes.

This year’s awardees include Stuart Arbuckle, Chief Operating Officer of Vertex Pharmaceuticals, who is recognized for overseeing global commercial functions—including market access, patient support, supply chain, and manufacturing—for therapies addressing cystic fibrosis, sickle cell disease, and other serious conditions. Marianne De Backer, Chief Executive Officer of Vir Biotechnology, stands out for leading the company’s strategic pivot toward infectious disease and oncology, drawing on decades of experience in R&D, licensing, and global M&A at Bayer and Johnson & Johnson. Meanwhile, Dan Kagan, President and Chief Operating Officer of Scientist.com, is acknowledged for building a widely adopted research outsourcing framework that powers the company’s global marketplace, used by top pharmaceutical companies, biotech firms, and the NIH.

Awardees were selected based on their strategic and operational leadership, contributions to therapeutic innovation and platform development, and ability to advance the broader field of biotechnology and life sciences. Please join us in celebrating The Top 25 BioTech and Life Sciences Executives of 2025.

15. Xiao-Jun Ma
Company: Alamar Biosciences
Title: Chief Technology Officer

Xiao-Jun Ma is the Chief Technology Officer of Alamar Biosciences, a privately held life sciences company developing high-sensitivity proteomics tools for early disease detection. Alamar’s platform includes its proprietary NULISA™ chemistry and the ARGO™ System, which together support automated, high-throughput protein analysis with qPCR and NGS readouts. The NULISAseq Inflammation Panel features over 200 immune and inflammatory markers and is designed for use on the ARGO System with minimal hands-on time.

Ma is a successful R&D leader with more than 20 years of experience in the life sciences and molecular diagnostics industries. Most recently he served as vice president and chief scientific officer in the Genomics Division of Bio-Techne, a pioneer in spatial genomics since its inception as Advanced Cell Diagnostics (ACD). During his 11-year tenure at ACD, Ma led the development of a world-leading portfolio of in situ RNA and DNA detection solutions for the research and clinical diagnostics markets.

Prior to joining ACD, he was vice president of R&D/biostatistics in bioTheranostics. Prior to bioTheranostics, Ma held senior bioinformatics positions at Johnson & Johnson and Monsanto/Searle (Pfizer), where he applied his multi-disciplinary knowledge in molecular biology and bioinformatics to discover novel drug targets and biomarkers. Ma received his doctorate training in biochemistry at Case Western Reserve University and the University of Iowa and post-doctoral training in molecular genetics at the University of California, Los Angeles.

read full article
Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.